Literature DB >> 6642787

Comparative bioavailability of carbimazole and methimazole.

R Jansson, P A Dahlberg, B Lindström.   

Abstract

In this study we investigated the oral bioavailability of therapeutic doses of two antithyroid drugs, methimazole and carbimazole, in seven euthyroid subjects. To increase the statistical power deuterium-labeled methimazole was given orally as an internal standard together with the tested drugs. Using a recently described highly sensitive gas chromatographic-mass spectrometric assay for methimazole we found that intake of 15 mg carbimazole resulted in plasma concentrations of methimazole and pharmacokinetic data comparable to intake of an equimolar amount of methimazole, i. e., 9.2 mg. Maximum concentrations of 163 and 149 ng/ml, respectively, were reached in both instances at 0.9 h after intake of 15 mg carbimazole and 10 mg methimazole. The plasma half-life was 5.7 and 5.4 h, respectively. In contrast to previous suggestions the interindividual differences in pharmacokinetics were small. In conclusion, carbimazole was rapidly and totally bioactivated to methimazole, and the drugs should be regarded as equipotent when compared on a molar basis.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6642787

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  9 in total

Review 1.  Acute and emergency care for thyrotoxicosis and thyroid storm.

Authors:  Alzamani Mohammad Idrose
Journal:  Acute Med Surg       Date:  2015-05-12

Review 2.  Breastfeeding and antithyroid drugs: a view from within.

Authors:  Spiros Karras; Gerasimos E Krassas
Journal:  Eur Thyroid J       Date:  2012-02-29

3.  Pharmacokinetic properties and bioavailability of methimazole.

Authors:  R Jansson; B Lindström; P A Dahlberg
Journal:  Clin Pharmacokinet       Date:  1985 Sep-Oct       Impact factor: 6.447

4.  Initial treatment of thyrotoxic Graves' disease with methimazole: a randomized trial comparing different dosages.

Authors:  M Messina; P Milani; L Gentile; A Monaco; C Brossa; M Porta; F Camanni
Journal:  J Endocrinol Invest       Date:  1987-06       Impact factor: 4.256

5.  Pharmacokinetics of methimazole in humans.

Authors:  J H Hengstmann; H Hohn
Journal:  Klin Wochenschr       Date:  1985-12-02

Review 6.  Neonatal thyroid disorders.

Authors:  A L Ogilvy-Stuart
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2002-11       Impact factor: 5.747

7.  Thyroxine, methimazole, and thyroid microsomal autoantibody titres in hypothyroid Hashimoto's thyroiditis.

Authors:  R Jansson; A Karlsson; P A Dahlberg
Journal:  Br Med J (Clin Res Ed)       Date:  1985-01-05

8.  Efficacy of Once Daily versus Divided Daily Administration of Low Daily Dosage (15 mg/Day) of Methimazole in the Induction of Euthyroidism in Graves' Hyperthyroidism: A Randomized Controlled Study.

Authors:  Sutin Sriussadaporn; Wanwaroon Pumchumpol; Raweewan Lertwattanarak; Tada Kunavisarut
Journal:  Int J Endocrinol       Date:  2017-12-18       Impact factor: 3.257

Review 9.  Management of Graves Thyroidal and Extrathyroidal Disease: An Update.

Authors:  George J Kahaly
Journal:  J Clin Endocrinol Metab       Date:  2020-12-01       Impact factor: 5.958

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.